76 related articles for article (PubMed ID: 17786634)
1. Cytochromes p450: roles in diseases.
Pikuleva IA; Waterman MR
J Biol Chem; 2013 Jun; 288(24):17091-8. PubMed ID: 23632021
[TBL] [Abstract][Full Text] [Related]
2. Codelivery of 1α,25-Dihydroxyvitamin D
Su Y; Ganguli-Indra G; Bhattacharya N; Logan IE; Indra AK; Gombart AF; Wong SL; Xie J
Mol Pharm; 2022 Mar; 19(3):974-984. PubMed ID: 35179903
[TBL] [Abstract][Full Text] [Related]
3. A convenient test system for the identification of CYP4V2 inhibitors.
Sharma S; Liu S; Durairaj P; Machalz D; Wolber G; Bureik M
Mol Vis; 2021; 27():601-607. PubMed ID: 34880593
[TBL] [Abstract][Full Text] [Related]
4. Variability in Loss of Multiple Enzyme Activities Due to the Human Genetic Variation P284T Located in the Flexible Hinge Region of NADPH Cytochrome P450 Oxidoreductase.
Parween S; Rojas Velazquez MN; Udhane SS; Kagawa N; Pandey AV
Front Pharmacol; 2019; 10():1187. PubMed ID: 31749697
[TBL] [Abstract][Full Text] [Related]
5. Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.
Rendic SP; Peter Guengerich F
Drug Metab Rev; 2018 Aug; 50(3):256-342. PubMed ID: 30717606
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor cell non-autonomously regulates
Pender CL; Horvitz HR
Elife; 2018 Jul; 7():. PubMed ID: 30010540
[TBL] [Abstract][Full Text] [Related]
7. Altered CYP19A1 and CYP3A4 Activities Due to Mutations A115V, T142A, Q153R and P284L in the Human P450 Oxidoreductase.
Udhane SS; Parween S; Kagawa N; Pandey AV
Front Pharmacol; 2017; 8():580. PubMed ID: 28970799
[TBL] [Abstract][Full Text] [Related]
8. Cistromic and genetic evidence that the vitamin D receptor mediates susceptibility to latitude-dependent autoimmune diseases.
Booth DR; Ding N; Parnell GP; Shahijanian F; Coulter S; Schibeci SD; Atkins AR; Stewart GJ; Evans RM; Downes M; Liddle C
Genes Immun; 2016 Jun; 17(4):213-9. PubMed ID: 26986782
[TBL] [Abstract][Full Text] [Related]
9. Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.
Hargrove TY; Wawrzak Z; Alexander PW; Chaplin JH; Keenan M; Charman SA; Perez CJ; Waterman MR; Chatelain E; Lepesheva GI
J Biol Chem; 2013 Nov; 288(44):31602-15. PubMed ID: 24047900
[TBL] [Abstract][Full Text] [Related]
10. Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs.
Rassnick KM; Muindi JR; Johnson CS; Bailey DB; Trump DL
Cancer Chemother Pharmacol; 2011 Jan; 67(1):165-71. PubMed ID: 20306264
[TBL] [Abstract][Full Text] [Related]
11. Genome mining in Sorangium cellulosum So ce56: identification and characterization of the homologous electron transfer proteins of a myxobacterial cytochrome P450.
Ewen KM; Hannemann F; Khatri Y; Perlova O; Kappl R; Krug D; Hüttermann J; Müller R; Bernhardt R
J Biol Chem; 2009 Oct; 284(42):28590-8. PubMed ID: 19696019
[TBL] [Abstract][Full Text] [Related]
12. Identification and structural basis of the reaction catalyzed by CYP121, an essential cytochrome P450 in Mycobacterium tuberculosis.
Belin P; Le Du MH; Fielding A; Lequin O; Jacquet M; Charbonnier JB; Lecoq A; Thai R; Courçon M; Masson C; Dugave C; Genet R; Pernodet JL; Gondry M
Proc Natl Acad Sci U S A; 2009 May; 106(18):7426-31. PubMed ID: 19416919
[TBL] [Abstract][Full Text] [Related]
13. A highly sensitive fluorogenic probe for cytochrome P450 activity in live cells.
Yatzeck MM; Lavis LD; Chao TY; Chandran SS; Raines RT
Bioorg Med Chem Lett; 2008 Nov; 18(22):5864-6. PubMed ID: 18595692
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cytochromes p450: existing and new promising therapeutic targets.
Schuster I; Bernhardt R
Drug Metab Rev; 2007; 39(2-3):481-99. PubMed ID: 17786634
[TBL] [Abstract][Full Text] [Related]
15. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications.
Hollenberg PF; Kent UM; Bumpus NN
Chem Res Toxicol; 2008 Jan; 21(1):189-205. PubMed ID: 18052110
[TBL] [Abstract][Full Text] [Related]
17. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1.
Shimada T; Yamazaki H; Foroozesh M; Hopkins NE; Alworth WL; Guengerich FP
Chem Res Toxicol; 1998 Sep; 11(9):1048-56. PubMed ID: 9760279
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of chemicals as inhibitors of trout cytochrome P450s.
Miranda CL; Henderson MC; Buhler DR
Toxicol Appl Pharmacol; 1998 Feb; 148(2):237-44. PubMed ID: 9473531
[TBL] [Abstract][Full Text] [Related]
19. Application of support vector machines to in silico prediction of cytochrome p450 enzyme substrates and inhibitors.
Yap CW; Xue Y; Li ZR; Chen YZ
Curr Top Med Chem; 2006; 6(15):1593-607. PubMed ID: 16918471
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
